Is Galectin Therapeutics Inc. overvalued?

Galectin Therapeutics Inc. (GALT) — key valuation metrics and fundamentals.

No verdict

Price

$3.93

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$258.8M

Dividend yield

0.0%

Return on equity

21.5%

Sector

Healthcare

Fair value compares GALT's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.

Related stocks